Long-term weight outcomes in patients treated with liraglutide 3.0 mg in real-world clinical practice.

Autor: Grannell A; Sidekick Health, Medical & Research Department, Kópavogur, Iceland.; UCD Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland., Al-Najim W; UCD Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland., le Roux C; UCD Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland.

Publikováno v: Clinical obesity [Clin Obes] 2024 Feb; Vol. 14 (1), pp. e12622. Date of Electronic Publication: 2023 Aug 24.

Laxative Properties of Microencapsulated Oleic Acid Delivered to the Distal Small Intestine in Patients with Constipation after Bariatric Surgery or Treatment with Glucagon-Like- Peptide 1 Analogues.

Autor: Al-Humadi AW; Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland., Al-Najim W; Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland.; Diabetes Research Centre, Ulster University, Coleraine, BT52 1SA, UK., Bleiel S; AnaBio Technologies Ltd, Carrigtwohill, Cork, T45 RW24, Ireland., le Roux CW; Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland. carel.leroux@ucd.ie.; Diabetes Research Centre, Ulster University, Coleraine, BT52 1SA, UK. carel.leroux@ucd.ie.

Publikováno v: Obesity surgery [Obes Surg] 2024 Oct; Vol. 34 (10), pp. 3807-3812. Date of Electronic Publication: 2024 Sep 05.

Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial.

Autor: Papamargaritis D; Diabetes Research Centre, Leicester General Hospital, University of Leicester College of Life Sciences, Leicester, UK.; National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and the University of Leicester, Leicester, UK.; Department of Diabetes and Endocrinology, Kettering General Hospital, University Hospitals of Northamptonshire NHS Group, Kettering, UK., Al-Najim W; Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland., Lim JZM; Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.; Diabetes, Endocrinology, and Metabolism Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, UK., Crane J; Diabetes, Endocrinology and Obesity (DEO) Clinical Academic Partnership, King's Health Partners, Guy's & St Thomas' Hospital, London, UK., Bodicoat DH; Independent Statistician, Leicester, UK., Barber S; Leicester Clinical Trials Unit, Leicester, UK., Lean M; School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK., McGowan B; Diabetes, Endocrinology and Obesity (DEO) Clinical Academic Partnership, King's Health Partners, Guy's & St Thomas' Hospital, London, UK., O'Shea D; Department of Endocrinology and Diabetes Mellitus, St Vincent's University Hospital, Dublin, Ireland., Webb DR; Diabetes Research Centre, Leicester General Hospital, University of Leicester College of Life Sciences, Leicester, UK.; National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and the University of Leicester, Leicester, UK., Wilding JPH; Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK., le Roux CW; Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland., Davies MJ; Diabetes Research Centre, Leicester General Hospital, University of Leicester College of Life Sciences, Leicester, UK.; National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and the University of Leicester, Leicester, UK.

Publikováno v: The Lancet regional health. Europe [Lancet Reg Health Eur] 2024 Feb 09; Vol. 39, pp. 100853. Date of Electronic Publication: 2024 Feb 09 (Print Publication: 2024).

Stratification of obesity phenotypes to optimize future therapy (SOPHIA).

Autor: Tahrani AA; Novo Nordisk A/S, søborg, Denmark., Panova-Noeva M; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany., Schloot NC; Lilly Deutschland GmbH, Bad Homburg, Germany., Hennige AM; Boehringer Ingelheim International GmbH, Biberach, Germany., Soderberg J; JDRF International., Nadglowski J; Obesity Action Coalition, Tampa, FL., Tarasenko L; Pfizer Inc, New York, NY, USA., Ahmad NN; Eli Lilly and Company, Indianapolis, IN, USA., Sleypen BS; Medtronic (Covidien AG)., Bravo R; Novo Nordisk A/S, søborg, Denmark., Al-Najim W; Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland., le Roux CW; Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland.

Publikováno v: Expert review of gastroenterology & hepatology [Expert Rev Gastroenterol Hepatol] 2023 Jul-Dec; Vol. 17 (10), pp. 1031-1039. Date of Electronic Publication: 2023 Oct 24.

Data from:The Effect of Macronutrient Type and Gastrointestinal Release Site on PYY Response in Normal Healthy Subjects

Autor: Mangan, Anna M., Al-Najim W, McNamara N, WP, Martin, Antanaitis A, Bleiel SB, RM, Kent, CW, Le Roux, Docherty, Neil

Cross tabulation of Statistical analysis of the relative effects of administration of gastric or small intestinal delivery of microencapsulated macronutrient on release of Peptide YY and food intake.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d9c987f32f9f7be48bae1aba5d9aa16